<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02742987</url>
  </required_header>
  <id_info>
    <org_study_id>CLOTILDIA</org_study_id>
    <nct_id>NCT02742987</nct_id>
  </id_info>
  <brief_title>Clopidogrel Versus Ticagrelor in Type-2 Diabetes</brief_title>
  <official_title>CLOpidogrel Versus TIcagreLor for Antiplatelet Maintenance in DIAbetic Patients Treated With Percutaneous Coronary Intervention: Results of the CLOTILDIA Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Campus Bio-Medico University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Campus Bio-Medico University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CLOTILDIA is a single-center, prospective, randomized, open label, cross-over study
      evaluating the effects of ticagrelor versus high-dose clopidogrel on endothelial function and
      platelet reactivity in patients with type-2 diabetes mellitus (T2DM) treated with
      percutaneous coronary intervention (PCI).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flow-mediated Dilation of the Brachial Artery</measure>
    <time_frame>4 weeks</time_frame>
    <description>Percent dilation of the brachial artery, as assessed with vascular ultrasound, from baseline to post-occlusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Flow-mediated Dilation of the Brachial Artery &lt;7%</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelium-independent Dilation of the Brachial Artery</measure>
    <time_frame>4 weeks</time_frame>
    <description>Percent dilation of the brachial artery, as assessed with vascular ultrasound, from baseline to post-administration of 0.5 mg sublingual nitroglycerin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Reactivity</measure>
    <time_frame>4 weeks</time_frame>
    <description>Platelet reactivity assessed with the VerifyNow P2Y12 Assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Platelet Reactivity &gt;256 P2Y12 Reaction Units</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Ticagrelor group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ticagrelor 90 mg twice daily + standard medical therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clopidogrel 150 mg once daily + standard medical therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Ticagrelor 90 mg twice daily</description>
    <arm_group_label>Ticagrelor group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Clopidogrel 150 mg once daily</description>
    <arm_group_label>Clopidogrel group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard medical therapy</intervention_name>
    <description>Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions</description>
    <arm_group_label>Ticagrelor group</arm_group_label>
    <arm_group_label>Clopidogrel group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 2 diabetes mellitus

          -  stable coronary disease

          -  coronary revascularization with PCI at least 1 month prior to recruitment

        Exclusion Criteria:

          -  acute coronary syndrome

          -  platelet count &lt;70x109/l

          -  active bleeding or bleeding diathesis

          -  history of intracranial bleeding

          -  gastrointestinal bleeding &lt;6 months

          -  cerebrovascular accident &lt;3 months

          -  history of malignancy

          -  concomitant need for oral anticoagulant therapy

          -  severe liver disease or chronic renal failure (glomerular filtration rate &lt;30 ml/min
             /1.73m2)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2016</study_first_submitted>
  <study_first_submitted_qc>April 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2016</study_first_posted>
  <results_first_submitted>July 18, 2017</results_first_submitted>
  <results_first_submitted_qc>July 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 17, 2017</results_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Campus Bio-Medico University</investigator_affiliation>
    <investigator_full_name>Germano Di Sciascio</investigator_full_name>
    <investigator_title>Prof. Germano Di Sciascio</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ticagrelor Group</title>
          <description>Ticagrelor 90 mg twice daily + standard medical therapy
Ticagrelor: Ticagrelor 90 mg twice daily
Standard medical therapy: Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions</description>
        </group>
        <group group_id="P2">
          <title>Clopidogrel Group</title>
          <description>Clopidogrel 150 mg once daily + standard medical therapy
Clopidogrel: Clopidogrel 150 mg once daily
Standard medical therapy: Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ticagrelor Group</title>
          <description>Ticagrelor 90 mg twice daily + standard medical therapy
Ticagrelor: Ticagrelor 90 mg twice daily
Standard medical therapy: Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions</description>
        </group>
        <group group_id="B2">
          <title>Clopidogrel Group</title>
          <description>Clopidogrel 150 mg once daily + standard medical therapy
Clopidogrel: Clopidogrel 150 mg once daily
Standard medical therapy: Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.9" spread="9.5"/>
                    <measurement group_id="B2" value="67.7" spread="8.1"/>
                    <measurement group_id="B3" value="66.8" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Flow-mediated Dilation of the Brachial Artery</title>
        <description>Percent dilation of the brachial artery, as assessed with vascular ultrasound, from baseline to post-occlusion</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor Group</title>
            <description>Ticagrelor 90 mg twice daily + standard medical therapy
Ticagrelor: Ticagrelor 90 mg twice daily
Standard medical therapy: Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel Group</title>
            <description>Clopidogrel 150 mg once daily + standard medical therapy
Clopidogrel: Clopidogrel 150 mg once daily
Standard medical therapy: Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions</description>
          </group>
        </group_list>
        <measure>
          <title>Flow-mediated Dilation of the Brachial Artery</title>
          <description>Percent dilation of the brachial artery, as assessed with vascular ultrasound, from baseline to post-occlusion</description>
          <units>FMD (%)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.6" spread="4.8"/>
                    <measurement group_id="O2" value="11.6" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Flow-mediated Dilation of the Brachial Artery &lt;7%</title>
        <time_frame>4 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endothelium-independent Dilation of the Brachial Artery</title>
        <description>Percent dilation of the brachial artery, as assessed with vascular ultrasound, from baseline to post-administration of 0.5 mg sublingual nitroglycerin</description>
        <time_frame>4 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Reactivity</title>
        <description>Platelet reactivity assessed with the VerifyNow P2Y12 Assay</description>
        <time_frame>4 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Platelet Reactivity &gt;256 P2Y12 Reaction Units</title>
        <time_frame>4 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ticagrelor Group</title>
          <description>Ticagrelor 90 mg twice daily + standard medical therapy
Ticagrelor: Ticagrelor 90 mg twice daily
Standard medical therapy: Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions</description>
        </group>
        <group group_id="E2">
          <title>Clopidogrel Group</title>
          <description>Clopidogrel 150 mg once daily + standard medical therapy
Clopidogrel: Clopidogrel 150 mg once daily
Standard medical therapy: Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Fabio Mangiacapra</name_or_title>
      <organization>Campus Bio-Medico University</organization>
      <phone>003906225411612</phone>
      <email>f.mangiacapra@unicampus.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

